EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Emerging Roles of the Stress Epigenetic Reader LEDGF/p75 in Cancer Biology and Therapy Resistance: Mechanisms and Targeting Opportunities

Greisha L Ortiz-Hernandez iD, Evelyn S Sanchez-Hernandez, Pedro T Ochoa, Carlos A Casiano iD

Cancers · 26.11.2024 · 16 (23) · 3957

DOI: 10.3390/cancers16233957 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 26.11.2024. Verfasst von Greisha L Ortiz-Hernandez und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for Health Disparities and Molecular Medicine, Department of Basic Sciences, Loma Linda University School of Medicine, Loma Linda, CA 92350, U…. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 173 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institutes of Health, USA, NCI NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The lens epithelium derived growth factor of 75 kD (LEDGF/p75) is a transcription co-activator and epigenetic reader that has emerged as a stress oncoprotein in multiple human cancers. Growing evidence indicates that it promotes tumor cell survival against certain therapeutic drugs. The amino (N)-terminal region of LEDGF/p75 contains a PWWP domain that reads methylated histone marks, critical for recognizing transcriptionally active chromatin sites. Its carboxyl (C)-terminus has an integrase binding domain (IBD) that serves as the binding site for the HIV-1 integrase and multiple oncogenic transcription factors. Acting as hubs for protein-protein interactions, both domains facilitate the tethering of oncogenic transcription factors and regulators to active chromatin to regulate mRNA splicing, promote DNA repair, and enhance the expression of stress and cancer-related genes that contribute to tumor cell aggressiveness and chemoresistance. This review summarizes our current knowledge of the emerging roles of LEDGF/p75 in cancer biology and therapy resistance and discusses its potential as a novel oncotherapeutic target in combinatorial treatments.

Schlagwörter

Stichwörter der Autor:innen

DFS70LEDGF/p75PSIP1PWWP domainRNA polymerase IIcancerchemoresistanceintegrase binding domaintherapeutic targeting

Autor:innen und Institutionen

  • Center for Health Disparities and Molecular Medicine, Department of Basic Sciences, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA.
  • Department of Medicine, Division of Rheumatology, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA.
  • Cancer Center, Loma Linda University Health, Loma Linda, CA 92350, USA.

ORCID-Profile: Greisha L Ortiz-Hernandez, Carlos A Casiano

Förderung

  • National Institutes of Health, USA
  • NCI NIH HHS
  • NIGMS NIH HHS
  • NIH
  • Loma Linda University Center for Health Disparities and Molecular Medicine

Zitieren

APA

Ortiz-Hernandez, G. L., Sanchez-Hernandez, E. S., Ochoa, P. T., & Casiano, C. A. (2024). The Emerging Roles of the Stress Epigenetic Reader LEDGF/p75 in Cancer Biology and Therapy Resistance: Mechanisms and Targeting Opportunities. Cancers, 16(23), 3957. https://doi.org/10.3390/cancers16233957

Vancouver

Ortiz-Hernandez GL, Sanchez-Hernandez ES, Ochoa PT, Casiano CA. The Emerging Roles of the Stress Epigenetic Reader LEDGF/p75 in Cancer Biology and Therapy Resistance: Mechanisms and Targeting Opportunities. Cancers. 2024;16(23):3957. doi:10.3390/cancers16233957

BibTeX
@article{OrtizHernandez2024,
  author = {Ortiz-Hernandez, Greisha L and Sanchez-Hernandez, Evelyn S and Ochoa, Pedro T and Casiano, Carlos A},
  title = {The Emerging Roles of the Stress Epigenetic Reader LEDGF/p75 in Cancer Biology and Therapy Resistance: Mechanisms and Targeting Opportunities},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {23},
  pages = {3957},
  doi = {10.3390/cancers16233957}
}
Kostenlos starten →